Aspirin and P2Y12 inhibitors in platelet-mediated activation of neutrophils and monocytes

Thrombosis and Haemostasis

Volumn 114, Issue 3, 2015, Pages 478-489

  Schrottmaier, Waltraud C ^a   Kral, Julia B ^a   Badrnya, Sigrun ^a   Assinger, Alice ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiplatelet agents; Aspirin; Inflammation; P2Y12 inhibitors; Platelet immunology; Platelet leukocyte interaction

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CD11B ANTIGEN; CD16 ANTIGEN; CD36 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CCR5; CLOPIDOGREL; COMPLEMENT COMPONENT C5A; FIBRINOGEN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PROSTAGLANDIN SYNTHASE; PURINERGIC P2Y12 RECEPTOR INHIBITOR; RANTES; REACTIVE OXYGEN METABOLITE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

ACUTE LUNG INJURY; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BACTEREMIA; BLEEDING; CELL INTERACTION; CROHN DISEASE; DENDRITIC CELL; GLOMERULONEPHRITIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY BOWEL DISEASE; KIDNEY DISEASE; LEUKOCYTE ACTIVATION; LIVER CELL CARCINOMA; LIVER DISEASE; LYMPHOCYTE; MONOCYTE; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; RESPIRATORY TRACT INFLAMMATION; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSPLANTATION; ANIMAL; BLOOD; CELL COMMUNICATION; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; METABOLISM; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPIRIN; BLOOD PLATELETS; CELL COMMUNICATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MONOCYTES; NEUTROPHIL ACTIVATION; NEUTROPHILS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; SIGNAL TRANSDUCTION;

EID: 84938108724     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-11-0943     Document Type: Article

References (127)

1. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circulation Res 2007; 100: 27–40
2. Karshovska E, et al. Platelet chemokines in health and disease. Thromb Haemost 2013; 110: 894–902
3. Rondina MT, et al. Platelets as cellular effectors of inflammation in vascular diseases. Circulation Res 2013; 112: 1506–1519
4. Zarbock A, et al. PSGL-1-dependent myeloid leukocyte activation. J Leukocyte Biol 2009; 86: 1119–1124
5. Rinder HM, et al. Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991; 78: 1730–1737
6. Li N. Platelet-lymphocyte cross-talk. J Leukocyte Biol 2008; 83: 1069–1078
7. van Gils JM, et al. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukocyte Biol 2009; 85: 195–204
8. Schulz C, et al. EMMPRIN (CD147/basigin) mediates platelet-monocyte interactions in vivo and augments monocyte recruitment to the vascular wall. J Thromb Haemost 2011; 9: 1007–1019
9. Haselmayer P, et al. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 2007; 110: 1029–1035
10. Burnier L, et al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439–451
11. Suzuki J, et al. Cytokine secretion from human monocytes potentiated by P-selectin- mediated cell adhesion. Intern Arch Allergy Immunol 2013; 160: 152–160
12. Weyrich AS, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97: 1525–1534
13. Lievens D, et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206–214
14. Pervushina O, et al. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J Immunol 2004; 173: 2060–2067
15. Vasina EM, et al. Aging- and activation-induced platelet microparticles suppress apoptosis in monocytic cells and differentially signal to proinflammatory mediator release. Am J Blood Res 2013; 3: 107–123
16. Badrnya S, et al. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. Arterioscl Thromb Vasc Biol 2014; 34: 571–580
17. Phillips JH, et al. Platelet-induced expression of Fc gamma RIII (CD16) on human monocytes. Eur J Immunol 1991; 21: 895–899
18. Yang J, et al. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomarker Res 2014; 2: 1
19. Gorbet MB, Sefton MV. Material-induced tissue factor expression but not CD11b upregulation depends on the presence of platelets. J Biomed Mater Res Part A 2003; 67: 792–800
20. Amirkhosravi A, et al. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemost 1996; 75: 87–95
21. Kasthuri RS, et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcgammaRI. Blood 2012; 119: 5285–5293
22. Barnard MR, et al. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost 2005; 3: 2563–2570
23. Huo Y, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nature Med 2003; 9: 61–67
24. Lievens D, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317–4327
25. Scheuerer B, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158–1166
26. Gleissner CA, et al. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 2010; 184: 4810–4818
27. Gleissner CA, et al. CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circulation Res 2010; 106: 203–211
28. Erbel C, et al. CXCL4-induced plaque macrophages can be specifically identified by co-expression of MMP7+S100A8+ in vitro and in vivo. Innate Immun 2014; Epub ahead of print.
29. Daub K, et al. Platelets induce differentiation of human CD34+ progenitor cells into foam cells and endothelial cells. FASEB J 2006; 20: 2559–2561
30. Gudbrandsdottir S, et al. Activated platelets enhance IL-10 secretion and reduce TNF-alpha secretion by monocytes. J Immunol 2013; 191: 4059–4067
31. Corken A, et al. Platelet glycoprotein Ib-IX as a regulator of systemic inflammation. Arterioscl Thromb Vasc Biol 2014; 34: 996–1001
32. Clark SR, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Med 2007; 13: 463–469
33. Zarbock A, et al. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev 2007; 21: 99–111
34. Ghasemzadeh M, et al. The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi. Blood 2013; 121: 4555–4566
35. Kulkarni S, et al. Conversion of platelets from a proaggregatory to a proinflammatory adhesive phenotype: role of PAF in spatially regulating neutrophil adhesion and spreading. Blood 2007; 110: 1879–1886
36. Diacovo TG, et al. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88: 146–157
37. Jy W, et al. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cell Mol Dis 1995; 21: 217–231
38. Duerschmied D, et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 2013; 121: 1008–1015
39. Rahman M, et al. Metalloproteinases regulate CD40L shedding from platelets and pulmonary recruitment of neutrophils in abdominal sepsis. Inflam Res 2012; 61: 571–579
40. Rahman M, et al. Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury. Ann Surg 2009; 250: 783–790
41. Maugeri N, et al. Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemic sclerosis. Antiox Redox Signal 2014; 20: 1060–1074
42. Lecut C, et al. ATP-gated P2X1 ion channels protect against endotoxemia by dampening neutrophil activation. J Thromb Haemost 2012; 10: 453–465
43. Assinger A, et al. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. J Thromb Haemost 2011; 9: 799–809
44. Manfredi AA, et al. Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. Curr Opin Hematol 2010; 17: 3–8
45. Mantovani A, et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Rev Immunol 2011; 11: 519–531
46. Brancaleone V, et al. A vasculo-protective circuit centered on lipoxin A4 and aspirin- triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 2013; 122: 608–617
47. Diacovo TG, et al. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996; 273: 252–255
48. Elzey BD, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003; 19: 9–19
49. Elzey BD, et al. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J Leukocyte Biol 2005; 78: 80–84
50. Shi G, et al. Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection. J Clin Invest 2014; 124: 543–552
51. Maitre B, et al. Immature myeloid dendritic cells capture and remove activated platelets from preformed aggregates. J Thromb Haemost 2010; 8: 2262–2272
52. Langer HF, et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscl Thromb Vasc Biol 2007; 27: 1463–1470
53. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010; 134: 25–32
54. Hagihara M, et al. Platelets, after exposure to a high shear stress, induce IL- 10-producing, mature dendritic cells in vitro. J Immunol 2004; 172: 5297–5303
55. Duffau P, et al. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Science Transl Med 2010; 2: 47ra63
56. Hamzeh-Cognasse H, et al. Direct contact of platelets and their released products exert different effects on human dendritic cell maturation. BMC Immunol 2008; 9: 54
57. Hilf N, et al. Human platelets express heat shock protein receptors and regulate dendritic cell maturation. Blood 2002; 99: 3676–3682
58. Yusuf S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502
59. Dovizio M, et al. Role of platelets in inflammation and cancer: novel therapeutic strategies. Basic Clin Pharmacol Toxicol 2014; 114: 118–127
60. Murugappa S, Kunapuli SP. The role of ADP receptors in platelet function. Front Biosci 2006; 11: 1977–1986
61. Santilli F, et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47: 391–397
62. Nannizzi-Alaimo L, et al. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003; 107: 1123–1128
63. Miedzobrodzki J, et al. Effect of nicotinamide and its two derivatives on the generation of reactive oxygen species in human monocytes cooperating with platelets. Acta Pol Pharm 2010; 67: 487–494
64. Badrnya S, et al. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein. Thromb Haemost 2012; 108: 719–729
65. Li N, et al. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165–170
66. Aktas B, et al. Aspirin induces platelet receptor shedding via ADAM17 (TACE). J Biol Chem 2005; 280: 39716–39722
67. Ratnatunga CP, et al. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation 1992; 85: 1077–1082
68. Heitzer T, et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006; 26: 1648–1652
69. Graff J, et al. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin Pharmacol Therap 2005; 78: 468–476
70. Evangelista V, et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet- dependent leukocyte activation. Thromb Haemost 2005; 94: 568–577
71. Frelinger AL, 3rd, et al. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost 2008; 6: 359–365
72. Klinkhardt U, et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73: 232–241
73. Braun OO, et al. Greater reduction of platelet activation markers and plateletmonocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 2008; 100: 626–633
74. Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015
75. Ortiz-Munoz G, et al. Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophilplatelet aggregation and attenuates acute lung injury in mice. Blood 2014; 124: 2625–2634
76. Gachet C. P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purin Signal 2012; 8: 609–619
77. Diehl P, et al. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res Cardiol 2010; 105: 379–387
78. Garcia AE, et al. Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment. PloS one 2013; 8: e69093
79. Harada K, et al. Adenosine diphosphate receptor P2Y12-mediated migration of host smooth muscle-like cells and leukocytes in the development of transplant arteriosclerosis. Transplantation 2011; 92: 148–154
80. Lukasik M, et al. Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. Thromb Res 2011; 128: e73–80
81. Sarafoff N, et al. Clinical use of clopidogrel. Curr Pharmaceut Des 2012; 18: 5224–5239
82. Willecke F, et al. Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in mice. Thromb Haemost 2014; 112: 379–389
83. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl 1): S13–33
84. Starlinger P, et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology 2014; 60: 257–266
85. Laschke MW, et al. Platelet-dependent accumulation of leukocytes in sinusoids mediates hepatocellular damage in bile duct ligation-induced cholestasis. Br J Pharmacol 2008; 153: 148–156
86. Zaldivar MM, et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010; 51: 1345–1353
87. Lang PA, et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nature Med 2008; 14: 756–761
88. Sitia G, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 2012; 109: E2165–2172
89. Sitia G, et al. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol 2013; 59: 1135–1138
90. Furuichi K, et al. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 2009; 13: 9–14
91. Peters H, et al. Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis. Kidney Int 2004; 65: 2238–2248
92. Zoja C, Remuzzi G. Role of platelets in progressive glomerular diseases. Ped Nephrol 1995; 9: 495–502
93. Voudoukis E, et al. Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. World J Gastroenterol 2014; 20: 3180–3190
94. Vowinkel T, et al. CD40-CD40 ligand mediates the recruitment of leukocytes and platelets in the inflamed murine colon. Gastroenterol 2007; 132: 955–965
95. Weissmuller T, et al. PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. J Clin Invest 2008; 118: 3682–3692
96. Patel SH, et al. Evaluation of anti-inflammatory effect of anti-platelet agentclopidogrel in experimentally induced inflammatory bowel disease. Indian J Pharmacol 2012; 44: 744–748
97. Ananthakrishnan AN, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Int Med 2012; 156: 350–359
98. Chan SS, et al. Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Therap 2011; 34: 649–655
99. Kasperska-Zajac A, et al. Platelet function in cutaneous diseases. Platelets 2008; 19: 317–321
100. Katoh N. Platelets as versatile regulators of cutaneous inflammation. J Dermatol Sci 2009; 53: 89–95
101. Tamagawa-Mineoka R, et al. Platelets play important roles in the late phase of the immediate hypersensitivity reaction. J Allergy Cin Immunol 2009; 123: 581–587, e1–9
102. Suzuki Y, Ra C. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: aspirin modulation of IgEdependent mast cell activation: role of aspirin-induced exacerbation of immediate allergy. J Pharmacol Sci 2009; 110: 237–244
103. Pamuk GE, et al. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud’s phenomenon and Raynaud’s phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul Fibrinol 2007; 18: 297–302
104. Saleh HM, et al. Platelet activation: a link between psoriasis per se and subclinical atherosclerosis--a case-control study. Br J Dermatol 2013; 169: 68–75
105. Ludwig RJ, et al. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004; 122: 830–836
106. Wu S, et al. Use of Aspirin, Nonsteroidal Anti-inflammatory Drugs, and Acetaminophen (Paracetamol), and Risk of Psoriasis and Psoriatic Arthritis: A Cohort Study. Acta Derm Venereol 2014; Epub ahead of print.
107. Mahajan VK, et al. Clopidogrel: a possible exacerbating factor for psoriasis. Indian J Pharmacol 2014; 46: 123–124
108. Pamuk GE, et al. Elevated platelet-monocyte complexes in patients with psoriatic arthritis. Platelets 2009; 20: 493–497
109. Joseph JE, et al. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115: 451–459
110. Kirk AD, et al. Platelets influence vascularized organ transplants from start to finish. Am J Transplant 2009; 9: 14–22
111. Yeaman MR. Platelets: at the nexus of antimicrobial defence. Nature Rev Microbiol 2014; 12: 426–437
112. Auerbach DJ, et al. Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor. Proc Natl Acad Sci USA 2012; 109: 9569–9574
113. Assinger A, et al. Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses. Arterioscl Thromb Vasc Biol 2014; 34: 801–809
114. Assinger A. Platelets and infection –an emerging role of platelets in viral infection. Front Immunol 2014; 5: 649
115. O’Brien M, et al. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acq Immune Def Syndr 2013; 63: 280–288
116. de Stoppelaar SF, et al. The role of platelets in sepsis. Thromb Haemost 2014; 112: 666–677
117. Fuchs TA, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880–1585
118. Xiang B, et al. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nature Commun 2013; 4: 2657
119. Weyrich AS, Zimmerman GA. Platelets in lung biology. Ann Rev Physiol 2013; 75: 569–591
120. Caudrillier A, Looney MR. Platelet-neutrophil interactions as a target for prevention and treatment of transfusion-related acute lung injury. Curr Pharmaceut Des 2012; 18: 3260–3266
121. Tuinman PR, et al. High-dose acetylsalicylic acid is superior to low-dose as well as to clopidogrel in preventing lipopolysaccharide-induced lung injury in mice. Shock 2013; 40: 334–338
122. Laidlaw TM, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012; 119: 3790–3798
123. Nieswandt B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295–1300
124. Rothwell PM, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591–1601
125. Wang Y, et al. Platelet P2Y12 is involved in murine pulmonary metastasis. PloS one 2013; 8: e80780
126. Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer 2015; 136: 234–240
127. Roop RP, et al. A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. Clin Breast Cancer 2013; 13: 409–415.